🇺🇸 Fosfomycin-Trometamol in United States

155 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Drug Ineffective — 17 reports (10.97%)
  2. Anxiety — 16 reports (10.32%)
  3. Condition Aggravated — 16 reports (10.32%)
  4. Rheumatoid Arthritis — 16 reports (10.32%)
  5. Diabetes Mellitus — 15 reports (9.68%)
  6. Feeling Abnormal — 15 reports (9.68%)
  7. Finger Deformity — 15 reports (9.68%)
  8. Foot Deformity — 15 reports (9.68%)
  9. Gait Disturbance — 15 reports (9.68%)
  10. Loss Of Personal Independence In Daily Activities — 15 reports (9.68%)

Source database →

Fosfomycin-Trometamol in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Fosfomycin-Trometamol approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Fosfomycin-Trometamol in United States?

Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH is the originator. The local marketing authorisation holder may differ — check the official source linked above.